Astrazeneca (AZN) Debt to Equity (2015 - 2025)
Astrazeneca (AZN) recorded quarterly Debt to Equity of -$0.44 in Q4 2025, down 162.86% quarter-over-quarter from $0.71 in Q4 2024, and down 162.86% on a YoY basis from $0.71 in Q4 2024.
Astrazeneca (AZN) Debt to Equity (2015 - 2025) Analysis & Trends
Astrazeneca's Debt to Equity history runs 11 years deep, the most recent figure standing at -$0.44 for Q4 2025.
- In Q4 2025, Debt to Equity fell 162.86% year-over-year to -$0.44; the TTM figure through Dec 2025 stood at -$0.44 (down 162.86% YoY), while the FY2025 annual figure was -$0.44, down 162.86% from the prior year.
- Debt to Equity was -$0.44 for Q4 2025 at Astrazeneca, down from $0.71 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.76 in Q4 2022 to a low of -$1.54 in Q2 2021.
- Historically, Debt to Equity has averaged -$0.13 across 5 years, with a median of -$0.44 in 2025.
- The sharpest annual moves came in 2021 and 2025: Debt to Equity surged 177.73% in 2021, then sank 162.86% in 2025.
- A 5-year view of Debt to Equity shows it stood at $0.76 in 2021, then grew by 0.62% to $0.76 in 2022, then slipped by 8.01% to $0.7 in 2023, then gained by 0.53% to $0.71 in 2024, then sank by 162.86% to -$0.44 in 2025.
- The last three Debt to Equity figures came in at -$0.44 (Q4 2025), $0.71 (Q4 2024), and -$0.69 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 1.39 |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 0.68 |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -9.70 |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 1.07 |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 6.24 |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 0.94 |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 0.72 |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.22 |
| 10 | Astrazeneca | 72.15 Bn | 64.21 Bn | 12.61 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.44 |
| Dec 31, 2024 | 0.71 |
| Jun 30, 2024 | -0.69 |
| Dec 31, 2023 | 0.70 |
| Jun 30, 2023 | -0.65 |
| Dec 31, 2022 | 0.76 |
| Jun 30, 2022 | -0.74 |
| Dec 31, 2021 | 0.76 |
| Jun 30, 2021 | -1.54 |
| Dec 31, 2020 | -0.98 |
| Dec 31, 2019 | -0.82 |
| Dec 31, 2018 | -0.94 |
| Dec 31, 2017 | 0.67 |
| Dec 31, 2016 | -0.65 |
| Dec 31, 2015 | -0.52 |